Myovant Sciences
adverse reactions of women treated with and at a greater incidence than placebo | Myovant Sciences
Company
Deck Type
Sector
Industry
Deck date
August 2022
Slide
20 of 34
Related slides by other companies
Dare Bioscience
Investor Presentation
February 2023
what is the incidence | Dare Bioscience
Nuvalent
Investor Presentation
February 2024
preliminary safety profile favorable and consistent with the highly selective sparing design of phase no no treatment related no aes leading to dose reduction or discontinuation no treatment related dizziness treatment related adverse events in patient all treated patients nausea alt increased ast increased myalgia grade grade grade any grade data as for patients treated by adverse event alt alanine ast aspartate dose limiting including source a toxicity | Nuvalent
Theravance Biopharma
Investor Conference
November 2022
adverse events during randomized controlled phases | Theravance Biopharma
Nuvalent
Investor Presentation
January 2024
preliminary safety profile favorable and consistent with the highly selective sparing design of in no no treatment related no aes leading to dose eduction or or discontinuation ion no treatment related dizziness treatment related adverse events in patient all treated patients fatigue alt increased ast increased myalgia grade grade grade any grade data as for patients treated by adverse event alt alanine ast aspartate dose limiting toxicity including source a a | Nuvalent
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights